Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 701–800 of 1,000
Nasrazadani, A., Tidwell, R. S. S., Kai, M., Lim, B., Valero, V., Tripathy, D., Saleem, S., Debeb, B. G., Lucci, A., Woodward, W. A., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02162-y · Cited by 2
“Overall, however, outcomes are significantly inferior to historical data compared with non-IBC data [10–16].”
Self-citationBülbül, B., Ucun, B., Cangür, C., Yeğen, İ. T., Eren, O. Ö., Yılmaz, C., Gül, G., Erdoğan, A. P., Hafızoğlu, E. Ş., Gökmen, E., et al. (2025) · Current Oncology · doi:10.3390/curroncol32120709 · Cited by 2
“The synergistic inhibition of both ER signalling and CDK4/6 has proven highly effective in advanced breast cancer, forming the rational basis for their combined use [6].”
Pan, Y., Duan, C., Du, J., Zhang, J., Du, K., Zhang, C., Liu, Z., Zhang, W., Wang, B., Ren, Y., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19176-1 · Cited by 2
Median, D., Antone, N. Z., Volovăț, S. R., Mazilu, L., Negru, S. M., Curca, R. O., Nita, A. L., Pătru, R. I., Ungureanu, A., Lupu, V., et al. (2026) · Current Oncology · doi:10.3390/curroncol33020120 · Cited by 3
Bartsch, R., Dormann, C., Egle, D., Gampenrieder, S. P., Pristauz-Telsnigg, G., Rinnerthaler, G., Singer, C. F., & Gnant, M. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02726-8 · Cited by 2
Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids
Williamson, J., Pletneva, M., Kim, R. G., & Bhatia, R. (2026) · Case Reports in Oncological Medicine · doi:10.1155/crom/4222126 · Cited by 2
“Approximately 11% of patients on ribociclib experience Grade 3 or 4 liver toxicity, with 8%–9% of patients discontinuing the drug permanently as a result [3, 5].”
Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer
Akamandisa, M. P., Xia, M., Cheah, W., Wubbenhorst, B. S., D'Andrea, K. P., Fan, M., Shilan, J. S., Pueschl, D., Nayak, A., McKenzie, H., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.203005 · Cited by 2
“In ER-positive, HER2-negative tumors, adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy improve invasive disease–free survival in early-stage disease, and significantly increase OS in metastatic disease, compared with endocrine therapy alone (31–34).”
Pontolillo, L., Munzone, E., Vigneri, P. G., Pistelli, M., Palazzo, A., Verde, N. M. L., Mazzotta, M., Paris, I., Alesini, D., Santini, D., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104817 · Cited by 3
Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer
Lei, L., Canning, M. T., Sakach, E. A., Lateef, A., Kamga, L., Abid, M., Kalinsky, K. M., & Gandhi, S. (2026) · Drugs · doi:10.1007/s40265-026-02347-5 · Cited by 2
Park, S., Park, J., Yang, S., Shin, J., & Koh, H. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1826917 · Cited by 2
Endocrine Therapy for Breast Cancer
Noe, J. F., & Bush, M. A. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.10.015 · Cited by 3
Adjuvant abemaciclib‑induced pneumonitis: A case report and review of the literature
Alghabban, A., Alshibany, A., Al‐Shangiti, K., Aseafan, M., Latif, K., & Al‐Tweigeri, T. (2021) · World Academy of Sciences Journal · doi:10.3892/wasj.2021.99 · Cited by 3
Schneeweiß, A., Fasching, P. A., Thill, M., van Mackelenbergh, M., Marmé, F., Tesch, H., Fehm, T. N., Park‐Simon, T., Häberle, L., Uhrig, S., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06246-2 · Cited by 2
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
Vetter, M. H. F., Rothgiesser, K., Li, Q., Hawle, H., Schönfeld, W., Ribi, K., Riniker, S., von Moos, R., Trojan, A., Kralidis, E., et al. (2022) · Endocrine Oncology · doi:10.1530/eo-21-0009 · Cited by 2
The history of targeted therapy
Gerk, I. (2023) · Practical oncology · doi:10.31917/2402119 · Cited by 2
Untch, M., Würstlein, R., Lüftner, D., Haidinger, R., Fasching, P. A., Augustin, D., Briest, S., Ettl, J., Forster, F. M. C., Kurbacher, C. M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1139-9380 · Cited by 3
“However, given the now documented survival benefit of an endocrine-based combination therapy with a CDK4/6 inhibitor [21,22], the majority (90.”
InfluentialSelf-citationKolyadina, I. V., & Poddubnaya, I. V. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-29-61-73 · Cited by 2
Lee, J., Im, S., Kim, G. M., Jung, K. H., Kang, S. Y., Park, I. H., Kim, J. H., Ahn, H. K., & Park, Y. H. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.1246 · Cited by 2
“34), favoring a placebo over ribociclib [22].”
Self-citationPreparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor Therapy
Yu, F., Zhang, T., Fu, F., Wang, A., & Liu, X. (2021) · Current Drug Delivery · doi:10.2174/1567201819666211224113311 · Cited by 3
Li, B., & Zheng, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14269 · Cited by 2
Андреевна, К. А., & Bokova, S. E. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.1.201440 · Cited by 2
Therapeutic Implications of CDKs in Breast Cancer
Mir, M. A., & Haq, B. U. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_11 · Cited by 2
Liu, W., Zhang, R., Yu, X., Zhang, Y., Kang, T., & Liao, D. (2023) · Medical Oncology · doi:10.1007/s12032-023-02133-3 · Cited by 2
Wang, Y., Zou, X., Mao, Y., Lv, M., & Li, W. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2790 · Cited by 2
Bhatia, K. P., & Batra, A. (2025) · Springer eBooks · doi:10.1007/978-981-97-9847-6_15 · Cited by 2
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1036-0961 · Cited by 2
Florilège des actualités oncologiques internationales en 2019
Magné, N., Sabatier, R., Wislez, M., André, T., Rodrigues, M. J., Hervé, L., Thiery-Vuillemin, A., Penel, N., Bouleuc, C., & Bay, J. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.01.010 · Cited by 2
“[2] - Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M et al.”
BackgroundLüftner, D., Schneeweiß, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., et al. (2020) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1199-2881 · Cited by 2
Opportunities for Antigen Discovery in Metastatic Breast Cancer
Sood, A. K., Nemeth, M. J., Wang, J., Wu, Y., & Gandhi, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570049 · Cited by 2
“2% for endocrine therapy plus ribociclib group compared to 46% for endocrine therapy alone group, after 42 months of follow-up period (21).”
BackgroundPost San Antonio update—my top three abstracts!
Suppan, C. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00718-0 · Cited by 2
Breast cancer liver metastasis: time to resection and criteria
Giovinazzo, F., Bucaro, A., & Agnes, S. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-372 · Cited by 2
“Several protocols are available based on the expression of BC molecular phenotypes (endocrine-responsive metastatic breast cancer, HER2-positive metastatic breast cancer, and metastatic triple-negative breast cancer) (Table 1) (5-9).”
Sammons, S. L., Yardley, D. A., Sharma, P., Gadi, V. K., Pegram, M. D., Pathak, P., Hu, H., Sopher, G. M., & Fasching, P. A. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00394-8 · Cited by 2
Ocen, J., & Kumar, S. (2020) · Medicine · doi:10.1016/j.mpmed.2019.11.008 · Cited by 1
Lê, Đ. D., & Lan, N. T. (2023) · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế · doi:10.38103/jcmhch.88.1 · Cited by 1
Ribociclib in newly diagnosed hepatitis B infection: A case report
Costanzo, F. D., Carrano, S., Iengo, G., Cefaliello, A., Cossiga, V., Morisco, F., Giuliano, M., Angelis, C. D., & Arpino, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1184952 · Cited by 1
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach, E. A., Keskinkılıç, M., Wood, S. J., Canning, M. T., & Kalinsky, K. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01109-9 · Cited by 1
Parsonson, A. O., Sarkar, S., Brown, L., Low, G. K. K., Kiely, B. E., & Vasista, A. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14096 · Cited by 1
Chae, H., Sim, S. H., Kwon, Y., Lee, E., Han, J., Jung, S., Lee, S., Kang, H., Kim, Y.-J., Kim, T. H., et al. (2024) · Cancers · doi:10.3390/cancers16183122 · Cited by 1
Self-citationModels of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing
Zapatero‐Solana, E., Ding, Y. P., Pulliam, N., de Dios, A., Ortiz-Ruiz, M. J., & Lallena, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062643 · Cited by 2
Hou, P.-Y. (2025) · Life · doi:10.3390/life15050709 · Cited by 1
“CDK4/6i combined with endocrine therapy has demonstrated PFS and OS benefit for HR-positive and HER2-negative advanced breast cancer, as confirmed by the PALOMA, MONALEESA, and MONARCH trials [1–5].”
Thérapies ciblées en situation néoadjuvante dans le cancer du sein : place des iCDK4/6 et des iPARP
Papazyan, T., & Frenel, J. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.06.005 · Cited by 1
King, J. P., Fakhouri, W., Jarvis, R., Badreldin, W., Harper, G., Palmieri, C., & Nathan, M. (2025) · BMC Cancer · doi:10.1186/s12885-025-14526-w · Cited by 1
“CDK4/6 inhibitors combined with endocrine therapy are now standard-of-care for patients with HR+, HER2-ABC/MBC in the first-line (1 L) or second-line (2 L) settings [2, 5–21].”
Ambere, G. D., Prajapati, D. N., Mathure, D. M., & Kumar, D. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101235 · Cited by 1
Michel, L. L., Ziegler, P., Kreis, P., Hartkopf, A. D., Wallwiener, M., Häberle, L., John, N., Kolberg, H., Hadji, P., Tesch, H., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115689 · Cited by 1
Shahbar, A. N. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251368239 · Cited by 1
Balla, E., Li, Y., Zhou, Z., Nguyen, J. T., Papadopoulou, K., Razis, E. D., Koutras, A. K., Galani, E. P., Mountzios, G., Romanidou, O., et al. (2025) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2025.100560 · Cited by 1
O’Connor, T. N., Schultz, E., Kabraji, S. K., Levine, E., Williams, A. J., Knudsen, E. S., & Witkiewicz, A. K. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00346 · Cited by 3
Bisht, V. S., Kumar, D., Vats, D., Nayak, D., & Ambatipudi, K. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124321 · Cited by 1
Jacob, S., Mayer, E. L., Kacik, N., Storniolo, A. M., Isaacs, C., Mayer, I. A., Stearns, V., Nanda, R., Nangia, J. R., Chien, A. J., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106063 · Cited by 1
Ji, Y., Huth, F., Wang, C., Schiller, H., Combes, F. P., Crown, J., Fasching, P. A., Zarate, J. P., & Untch, M. (2026) · Pharmaceuticals · doi:10.3390/ph19030461 · Cited by 1
“…with ET, ribociclib has demonstrated consistent, statistically significant, and clinically meaningful improvement in progression-free survival and overall survival over ET alone in the phase 3 MONALEESA-2, -3, and -7 trials in patients with HR+/HER2 − advanced breast cancer (ABC) [8–10].”
How I Read a Clinical Trial Report? A Primer for Busy Clinicians
Gyawali, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00181 · Cited by 1
Özbay, E. K., Öztürk, B., Ozbay, M. F., Doğan, B., Küçük, M. F., Ovali, F. S., & Karaca, M. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.06.020 · Cited by 1
Yang, Y., Zhu, S., Fu, Z., Sun, C., Yang, F., Zeng, T., Hua, Y., Bao, S., Gao, X., Huang, X., et al. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-54 · Cited by 1
“The MONALEESA-7 (22,23) trial, for the first time, compares an NSAI or tamoxifen plus goserelin in combination with CDK4/6 inhibitor or placebo in premenopausal and perimenopausal patients with HR+/ HER2− advanced breast cancer.”
BackgroundInfluentialMaladie thromboembolique veineuse et cancer du sein
Crichi, B., Moati, É., Cacciatore, C., Farge, D., & Frère, C. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.06.001 · Cited by 1
Rebegea, L. F., Firescu, D., Trifanescu, O. G., Rahnea-Niță, R.-A., Bîlteanu, L., Dumitru, M., Lacatus, F., & Nita, G. (2025) · Journal of Mind and Medical Sciences · doi:10.3390/jmms12010033 · Cited by 1
Zhang, J., Liu, R., Gao, S., Chen, W., Han, X., Wang, Z., Zhou, H., Wang, Y., Chen, J., Ma, Y., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105121 · Cited by 2
Villarreal-Garza, C. M., Meraz-Brenez, A., Reyes-Morales, A., Mushtaq, A. W., Moreno‐Jaime, B., Landaverde, D., Petracci, F. E., Idrobo, H., Moreno-Ríos, J., Pérez-Vargas, J. C. S., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00425 · Cited by 1
Beshr, M. S., Fahaid, A., Shembesh, R. H., Valachis, A., Lambertini, M., Cortesi, L., Alesawy, A. F., Abraheem, A., Alsharedi, M. F., Ali, M. E., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00053-7 · Cited by 2
Wang, Y., Zhang, M., Zhang, X., Guo, T., Wang, Y., & YU, C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105497 · Cited by 1
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 2
“The trial demonstrated significant improvements in both PFS (mPFS 23.8 versus 13.0 months; HR 0.55; 95% CI 0.44–0.69; P < 0.001) and OS (mOS 58.7 versus 48.0 months; HR 0.76; 95% CI 0.61–0.96), making this the first CDK4/6i trial to demonstrate OS benefit in patients pre-menopause [19, 24, 32].”
InfluentialAbdel‐Razeq, H., Abunasser, M., Farfoura, H., Abdel-Razeq, R., & Khzouz, J. N. (2021) · Cureus · doi:10.7759/cureus.14088 · Cited by 1
“Ribociclib was the first among the three to demonstrate a survival advantage in both premenopausal and postmenopausal settings [9,10].”
BackgroundUpdate Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom
Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Thomssen, C., Müller, V., Fehm, T. N., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1816-1687 · Cited by 1
Endokrine Therapien beim Mammakarzinom
Stettler, S., & Aebi, S. P. (2022) · Praxis · doi:10.1024/1661-8157/a003878 · Cited by 2
Fabi, A., Buono, G., Bria, E., Bianchini, G., Curigliano, G., Laurentiis, M. D., Placido, S. D., Mastro, L. D., Guarneri, V., Generali, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950861 · Cited by 1
“Consistently with MONALEESA 2, data from MONALEESA-7 (14), also showed a PFS and OS advantage in premenopausal women treated with ribociclib + ET (tamoxifen or AI+ aLHRH) vs ET alone, further strengthen confidence in Frontiers in Oncology 08 the use of AIs in association to CDK4/6i regardless the menopausal status in…”
MethodInfluentialAhmed, S. S., Majumdar, S. K. D., Dhar, S. S., Mahapatra, B. R., Muraleedharan, A. K., Barik, S. K., & Parida, D. K. (2022) · Indian Journal of Case Reports · doi:10.32677/ijcr.v8i9.3590 · Cited by 1
Chemotherapeutic Protocols for the Treatment of Breast Cancer
Cavalcanti, I. D. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-10839-6_4 · Cited by 2
Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors
Droste, A., & Schmidt, M. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.94 · Cited by 1
CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis
Mir, M. A., Sofi, S., & Ishfaq, P. M. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_8 · Cited by 1
Tagliaferri, B., Mollica, L., Palumbo, R., Leli, C., Malovini, A. L., Terzaghi, M., Quaquarini, E., Teragni, C. M., Maccarone, S., Premoli, A., et al. (2023) · Drugs in Context · doi:10.7573/dic.2023-1-7 · Cited by 1
Goryainova, А. Y., Murashko, R. A., Викторович, Ш. С., Stukan, А. I., Kugaevsky, D. N., & Lymar, Е. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-201 · Cited by 1
Lin, H., Wu, W., Lou, X.-Y., Wang, Y., Sun, H., Cai, J., Liu, S., & Wei, X. (2024) · The Breast · doi:10.1016/j.breast.2024.103680 · Cited by 2
“Second, the STIC CTC trial was conducted before the results of pivotal trials of first-line cyclin-dependent kinase 4/6 (CDK4/6) inhibitors [40,41].”
MethodCáncer de mama luminal: estado del arte
Bravo-Garzón, M. A., Mantilla, W. A., Cervera, S., Caicedo, J. J., & Franco, S. X. (2023) · Medicina · doi:10.56050/01205498.2315 · Cited by 3
Savvidou, A., Theophanous-Kitiri, S., Zacharia, L. C., Constantinidou, A., & Petrou, C. C. (2024) · European Journal of Oncology Pharmacy · doi:10.1097/op9.0000000000000054 · Cited by 1
Norman, A., Seetharam, M., Allred, J. B., Kong, J., Opyrchal, M., Ma, W. W., Lou, Y., Dy, G. K., Mahipal, A., Weroha, S. J., et al. (2025) · BJC Reports · doi:10.1038/s44276-024-00107-0 · Cited by 1
“CDK4/6 inhibitors have been approved for treatment of hormone receptor positive metastatic breast cancer in combination with hormonal blockade agents [7 – 10].”
Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis
Ceylan, F., Mehdiyev, M., Bilgin, B., Tenekeci, A. K., Yalçın, B., Akıncı, M. B., Dede, D. Ş., Şendur, M. A. N., Algın, E., & Yücel, Ş. (2025) · Cancers · doi:10.3390/cancers17030424 · Cited by 2
“This is lower than the incidences reported in clinical trials for ribociclib, where grade ≥ 3 neutropenia was seen in 64% of patients in both the MONALEESA-2 [2] and MONALEESA-7 [26] trials and 54% in the MONALEESA-3 trial [23].”
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer
Yarlagadda, S. R., Andrade, M. D. O., & Nanda, R. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2498994 · Cited by 1
“Premenopausal women were studied in the phase III MONALEESA-7 [7,36,37] trial evaluating ribociclib or placebo with ET.”
Lee, J., Lee, D.-W., Kim, M. H., Kim, J. H., Kim, J., Byun, J.-H., Lee, K. E., Kang, M. J., Koh, S.-J., Hong, S., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104500 · Cited by 1
“In Korea, only ribociclib + AI + gonadotropin-releasing hormone agonist (GnRHa) is approved and reimbursed as first line treatment in premenopausal women, based on MONALEESA-7 [28,29].”
Self-citationGuo, L., Dai, Y., Xiao, M., Li, Z., Mao, Y., Zhu, Z., Xu, X., & Peng, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1661867 · Cited by 1
From the 2019 ASCO Annual Meeting
Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0245-x · Cited by 1
Refractory Bone Marrow Involvement Responding to Ribociclib and Tamoxifen in Advanced Breast Cancer
Dhanushkodi, M., & Velusamy, S. (2019) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-019-0318-x · Cited by 1
“Ribociclib is the only CDK 4/6 inhibitor that has shown an overall survival benefit in combination with endocrine therapy [12].”
BackgroundBanys‐Paluchowski, M. (2020) · Der Onkologe · doi:10.1007/s00761-019-00706-4 · Cited by 1
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
Álvarez, I., Bezares, S., Dalmau, E., García-Martínez, E., García-Sáenz, J. Á., Gil‐Gil, M., de Dueñas, E. M., Ribelles, N., & Santaballa, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02269-7 · Cited by 2
Angelis, C. D., Ignatiadis, M., & Piccart, M. J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3216 · Cited by 1
“Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy represents nowadays the standard of care for pre- and postmenopausal women with HR-positive/HER2-negative advanced breast cancer both in the first- and secondline setting (2-5).”
BackgroundAgostinetto, E., & Ignatiadis, M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.002 · Cited by 1
Poddubnaya, I. V., Gligorov, J., Zhukova, L., Kovalenko, E. I., & Фролова, М. А. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200568 · Cited by 1
Actualidades en el manejo sistémico del cáncer de mama
Luna-Palencia, R. L., & la Cruz-Escobar, E. N. D. (2020) · Revista Mexicana de Mastología · doi:10.35366/99156 · Cited by 1
Moisander, M., Salminen, A., Jukkola‐Vuorinen, A., Sassi, A., Tervo, M., Mäenpää, N., Tiainen, L., Rinta-Kiikka, I. C., Tolonen, T. T., & Arponen, O. (2021) · Acta Radiologica Open · doi:10.1177/20584601211030660 · Cited by 1
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac106.68106820 · Cited by 1
Belac-Lovasić, I., Bašić-Koretić, M., Podolski, P., Plavetić, N. D., Silovski, T., Pleština, S., Jazvić, M., Soldić, Ž., Šeparović, R., Vuger, A. T., et al. (2022) · Liječnički vjesnik · doi:10.26800/lv-144-9-10-2 · Cited by 2
Peng, T., Chen, J., & Wu, T. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15090 · Cited by 2
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Bartsch, R., Rinnerthaler, G., Petru, E., Egle, D., Gnant, M., Balić, M., Sliwa, T., & Singer, C. F. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02254-9 · Cited by 2
Wysocki, P. J. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.97946 · Cited by 2
Differences of palbociclib and ribociclib in terms of cell death pathways; a cell culture assayPreprint
Özlük, A. A., Bulut, G., Atmaca, H., & Karaca, S. (2020) · Research Square · doi:10.21203/rs.3.rs-122837/v1 · Cited by 1
“In the study of MONALEESA-7, the contribution of ribociclib to non-progression survival was shown [9].”
BackgroundThe PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2Preprint
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C. M., et al. (2024) · eLife · doi:10.7554/elife.97577.2 · Cited by 3
Karna, B., Gentile, F., Gulde, S., Martino, D. D., Maurer, J., Ganesan, K., Wang, K., Bechmann, N., Rapizzi, E., Robledo, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.18.638668 · Cited by 1
“CDK4/6 inhibitors combined with aromatase inhibitors are approved as first-line treatment for HR+/HER2-advanced breast cancer, significantly improving progression-free and overall survival [72-74].”
Armand, J., Kim, S., Kim, K., Son, E., Kim, M., Kalinsky, K. M., & Yang, H. W. (2025) · eLife · doi:10.7554/elife.104545.2 · Cited by 2
Recent Developments in HER2-Directed Therapy in Breast Cancer
Kang, I. M., Dong, S., Lu, J. M., & Xia, B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00347-x · Cited by 35
Національний інститут раку, К., Smolanka, I. I., Ivankova, O. M., Національний інститут раку, К., Ігнат, М. В., Закарпатський обласний клінічний онкологічний диспансер, У., Ligirda, O. F., Національний інститут раку, К., Lyashenko, A. O., & Національний інститут раку, К. (2019) · Clinical Oncology · doi:10.32471/clinicaloncology.2663-466x.38.23213
CDK4/6-Inhibitoren beim metastasierten HR+/HER2- Mammakarzinom – Einer, keiner – oder irgendeiner?
Wormann, B. J., Brucker, S. Y., Lüftner, D., Schmidt, M., Tesch, H., & Welt, A. (2019) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1031-4522
“1093/annonc/mdy155 [22] Im SA, Lu YS, Bardia A et al.”
BackgroundStau am Östrogenrezeptor bei fortgeschrittenem Mammakarzinom: Ende der endokrinen Monotherapie
Lüftner, D., & Busse, A. (2020) · Der Onkologe · doi:10.1007/s00761-020-00730-9
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.